A 71-year-old man was referred for ablation of a long segment of Barrett’s esophagus, 6 cm in length, with confirmed multifocal low grade dysplasia. He was offered radiofrequency ablation (RFA) but declined this treatment as a family member had experienced extreme pain associated with RFA. Given cryotherapy is efficacious for Barrett’s ablation [1] and is associated with less pain than RFA [2, 3], the patient was offered cryotherapy, which he accepted.

The patient was treated with the next generation of cryoballoon device with the new standard 90 balloon (C2 Cryoballoon 90 ablation system; Pentax Medical, Redwood City, California, USA), which treats a large area (3 cm long, and approximately a quarter of the esophageal circumference) (▶ Fig. 1, ▶ Video 1). The new cryoballoon ablation system is commercially available in the United States and is approved by the US Food and Drug Administration. The entire segment was treated with low dose cryogen (0.9 mm/s on the right hemicircumference and 0.8 mm/s on the left) [4]. The patient tolerated the procedure well and had no post-procedure pain.

At the 3-month follow-up examination, only a few small islands of Barrett’s esophagus remained, and these were treated with the current generation focal cryoballoon (▶ Video 1). At the 6-month follow-up check, no Barrett’s remained.

Compared with the current generation focal cryoballoon, which freezes smaller areas approximately 2–3 cm in size, the standard 90 balloon improves upon the prior focal balloon in that a quarter of the esophageal circumference can be treated at a time for a length of up to 3 cm. The next-generation device is physician operated through a foot pedal (▶ Fig. 2). The physician controls the position and placement of the diffuser that releases the cryogen.

This case demonstrates that the next-generation cryoballoon ablation system enables successful treatment of wider and longer segments of Barrett’s esophagus. Studies are ongoing to determine optimal dosing strategies and technique.

Competing interests
Drs. Trindade and Canto are consultants for Pentax Medical/C2 Therapeutics.
The authors

Arvind J. Trindade1, Marcia I. Canto2
1 Division of Gastroenterology, Long Island Jewish Medical Center, Zucker School of Medicine at Hofstra/Northwell, Northwell Health System, New Hyde Park, New York, United States
2 Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

Corresponding author

Arvind J. Trindade, MD
Long Island Jewish Medical Center, Division of Gastroenterology, Zucker School of Medicine at Hofstra/Northwell, Northwell Health, New Hyde Park, NY 11040, United States
Fax: +718-470-5509
arvind.trindade@gmail.com

References


Bibliography
DOI https://doi.org/10.1055/a-0824-6058
Published online: 2019
Endoscopy
© Georg Thieme Verlag KG
Stuttgart · New York
ISSN 0013-726X

Video 1 Treatment of a long segment of Barrett’s esophagus using the next generation of cryoballoon ablation systems.

Fig. 2 The foot pedal allows the physician to control the placement of the diffuser to control the location of cryotherapy.